Structure‐Based Virtual Screening Approach to the Discovery of Novel Inhibitors of Eyes Absent 2 Phosphatase with Various Metal Chelating Moieties
暂无分享,去创建一个
Hwangseo Park | Suk-Kyeong Jung | J. Ko | Hwangseo Park | Suk-Kyeong Jung | Seung-Jun Kim | Keum R Yu | Ju H Kim | Yong-Sam Kim | Jeong H Ko | Byoung C Park | Seung J Kim | K. R. Yu | B. C. Park | Ju H. Kim | Yongsam Kim
[1] G. Mardon,et al. Eyes absent represents a class of protein tyrosine phosphatases , 2003, Nature.
[2] C. Lima,et al. The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. , 2008, Molecular cell.
[3] S. Batra,et al. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells , 2010, Oncogene.
[4] C. Allis,et al. Dephosphorylation of the C-terminal Tyrosyl Residue of the DNA Damage-related Histone H2A.X Is Mediated by the Protein Phosphatase Eyes Absent* , 2009, The Journal of Biological Chemistry.
[5] G. A. Jeffrey,et al. An Introduction to Hydrogen Bonding , 1997 .
[6] Hwanho Choi,et al. Prediction of Molecular Solvation Free Energy Based on the Optimization of Atomic Solvation Parameters with Genetic Algorithm , 2007, J. Chem. Inf. Model..
[7] S. Kim,et al. BeF(3)(-) acts as a phosphate analog in proteins phosphorylated on aspartate: structure of a BeF(3)(-) complex with phosphoserine phosphatase. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] Hwangseo Park,et al. Critical assessment of the automated AutoDock as a new docking tool for virtual screening , 2006, Proteins.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] P. Kollman,et al. A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .
[11] Ibon Alkorta,et al. Competition of hydrogen bonds and halogen bonds in complexes of hypohalous acids with nitrogenated bases. , 2008, The journal of physical chemistry. A.
[12] Joanna M. Sasin,et al. Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.
[13] Peter A. Kollman,et al. Application of the RESP Methodology in the Parametrization of Organic Solvents , 1998 .
[14] Suk-Kyeong Jung,et al. Crystal structure of ED‐Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] Henry H Nguyen,et al. Structural characterization of the reaction pathway in phosphoserine phosphatase: crystallographic "snapshots" of intermediate states. , 2002, Journal of molecular biology.
[16] I. Kuntz,et al. Ligand solvation in molecular docking , 1999, Proteins.
[17] C. Glass,et al. Eya protein phosphatase activity regulates Six1–Dach–Eya transcriptional effects in mammalian organogenesis , 2003, Nature.
[18] C. Supuran,et al. Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II. , 2006, Bioorganic & medicinal chemistry letters.
[19] J. Gasteiger,et al. Automatic generation of 3D-atomic coordinates for organic molecules , 1990 .
[20] I. Rebay,et al. The eyes absent family of phosphotyrosine phosphatases: properties and roles in developmental regulation of transcription. , 2007, Annual review of biochemistry.
[21] Yong Eun Kim,et al. A Structure‐Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc‐Chelating Groups , 2010, ChemMedChem.
[22] Dan S. Tawfik,et al. Protein Dynamism and Evolvability , 2009, Science.
[23] C. Sander,et al. An effective solvation term based on atomic occupancies for use in protein simulations , 1993 .
[24] C. Supuran,et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. , 2006, Journal of the American Chemical Society.
[25] Hwangseo Park,et al. Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. , 2005, Journal of the American Chemical Society.
[26] Andrea Scozzafava,et al. Carbonic anhydrase inhibitors. , 2001, Medicinal research reviews.
[27] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[28] R. Hegde,et al. Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis , 2009, Oncogene.
[29] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[30] R. Hegde,et al. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells , 2010, Oncogene.
[31] J. Selengut,et al. The transcription factor Eyes absent is a protein tyrosine phosphatase , 2003, Nature.
[32] Christopher K. Glass,et al. Tyrosine Dephosphorylation of H2AX Modulates Apoptosis and Survival Decisions , 2009, Nature.
[33] N. Yang,et al. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. , 2005, Cancer research.
[34] Q. Ye,et al. Drosophila Eyes Absent Homologue 2 is up-regulated in lung adenocarcinoma , 2009 .
[35] Biao Wu,et al. A new sulfonamide derivative as magnesium ion receptor: N -tosyl-2,6-diisopropyl-4-(2,3-dimethoxylbenzoylamide)aniline , 2009 .